OMICS. 2016 Apr 20. [Epub ahead of print]
An Alternative Methodological Approach for Cost-Effectiveness Analysis and Decision Making in Genomic Medicine.
Abstract
- PMID:
- 27096406
- [PubMed - as supplied by publisher]
aportes a la gestión necesaria para la sustentabilidad de la SALUD PÚBLICA como figura esencial de los servicios sociales básicos para la sociedad humana, para la familia y para la persona como individuo que participa de la vida ciudadana.
domingo, 1 de mayo de 2016
An Alternative Methodological Approach for Cost-Effectiveness Analysis and Decision Making in Genomic Medicine. - PubMed - NCBI
An Alternative Methodological Approach for Cost-Effectiveness Analysis and Decision Making in Genomic Medicine. - PubMed - NCBI
Genomic Medicine aims to improve therapeutic interventions and diagnostics, the quality of life of patients, but also to rationalize healthcare costs. To reach this goal, careful assessment and identification of evidence gaps for public health genomics priorities are required so that a more efficient healthcare environment is created. Here, we propose a public health genomics-driven approach to adjust the classical healthcare decision making process with an alternative methodological approach of cost-effectiveness analysis, which is particularly helpful for genomic medicine interventions. By combining classical cost-effectiveness analysis with budget constraints, social preferences, and patient ethics, we demonstrate the application of this model, the Genome Economics Model (GEM), based on a previously reported genome-guided intervention from a developing country environment. The model and the attendant rationale provide a practical guide by which all major healthcare stakeholders could ensure the sustainability of funding for genome-guided interventions, their adoption and coverage by health insurance funds, and prioritization of Genomic Medicine research, development, and innovation, given the restriction of budgets, particularly in developing countries and low-income healthcare settings in developed countries. The implications of the GEM for the policy makers interested in Genomic Medicine and new health technology and innovation assessment are also discussed.
No hay comentarios:
Publicar un comentario